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Abstract
Background and objective: Pain is a common symptom in patients who survive 
cancer and in those who live with progressive advanced disease. Evidence from 
meta‐analyses suggests that pain remains poorly controlled for a large proportion of 
patients; barriers to good management include poor assessment of pain, inadequate 
support for patient self‐management and late or inadequate access to strong opioid 
analgesia in those with advanced disease.
Methods: The European Pain Federation (EFIC) established a Task Force in 2017 
which convened a European group of experts, drawn from a diverse range of relevant 
clinical disciplines, to prepare a position paper on appropriate standards for the man-
agement of cancer‐related pain. The expert panel reviewed the available literature 
and made recommendations using the GRADE system to combine quality of evi-
dence with strength of recommendation. The panel took into account the desirable 
and undesirable effects of the management recommendation, including the cost and 
inconvenience of each when deciding the recommendation.
Results and conclusions: The 10 standards presented are aimed to improve cancer 
pain management and reduce variation in practice across Europe. The Task Force 
believes that adoption of these standards by all 37 countries will promote the quality 
of care of patients with cancer‐related pain and reduce unnecessary suffering.
Significance: Pain affects up to 40% of cancer survivors and affects at least 66% of 
patients with advanced progressive disease, many of whom experience poor pain 
control. These 10 standards are aimed to improve cancer pain management, promote 
the quality of care of patients and reduce variation across Europe.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2019 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of European Pain Federation - EFIC ®
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1 |  INTRODUCTION
Each year, approximately 3.45 million Europeans are di-
agnosed with cancer of whom 66% will survive for at least 
5 years and 40% will be alive more than 10 years after their 
diagnoses (Ferlay et al, 2013; Glare et al, 2014).
Pain is the commonest symptom of cancer at diagnosis 
(Breivik et al, 2009) and rises in prevalence throughout and 
beyond cancer treatment (van den Beuken‐van Everdingen 
et al, 2016). Between 33% and 40% of cancer survivors 
(persons with cancer whose curative treatment was com-
pleted) suffer from chronic pain (Boland and Ahmedzai, 
2017; Paice, 2011; Seretny et al, 2014). In contrast, 1.7 mil-
lion European cancer patients die from their disease each 
year of whom at least 66% will experience pain before death 
and 55% will experience moderate‐to‐severe intensity pain 
(Ferlay et al, 2013; van den Beuken‐van Everdingen et al, 
2016).
It is more than 30 years since the publication of the 
WHO method or guidelines for cancer pain relief (WHO, 
1996). Despite this and the publication of European guide-
lines (Caraceni et al, 2012; Raphael, Ahmedzai, et al, 2010; 
Ripamonti et al, 2012; Swarm et al, 2013), there remain bar-
riers to good control of cancer‐related pain (Oldenmenger 
et al, 2009). At least one‐third of patients are undertreated 
which is often due to inadequate attention to pain during reg-
ular oncological treatment, and inequitable or delayed access 
to opioids (Gagnon et al, 2015; Greco et al, 2014; Te Boveldt 
et al, 2015; Ziegler et al, 2016). Uncontrolled or undertreated 
pain may become physically and emotionally disabling, lead-
ing to increased suffering and reduced quality of life (Te 
Boveldt et al, 2013).
A Task Force was sourced by the European Pain 
Federation (EFIC) in 2017. In line with other standards de-
velopment groups, a panel of international experts was in-
stituted, chaired by EE and MB. Experts from European 
countries were invited by email to participate, explaining the 
rationale for the process, and aiming for broad geographical 
representation within Europe.
EFIC recognizes that improving the experience of pa-
tients with cancer‐related pain requires actions that focus 
on patients, clinicians and healthcare providers or systems. 
The EFIC Task Force on cancer‐related pain reviewed ex-
isting evidence‐based guidelines and reached a consensus 
on the standards for the management of cancer‐related pain 
across all 37 European countries that are members of the 
European Pain Federation (EFIC). This paper describes 10 
standards that EFIC member countries should institute or 
be working towards. The standards do not specify which 
healthcare professional(s) should conduct assessments, 
agree management plans, provide tailored treatment and 
support, or refer for more specialized advice and treatment. 
The Task Force considered that all services involved in the 
care of patients with cancer should consider how best to 
meet these standards considering local expertise and re-
sources. These standards may also prompt greater collabo-
ration between clinicians in pain medicine, palliative care 
and oncology to meet the needs of patients with cancer‐re-
lated pain.
The GRADE (Grading of Recommendations Assessment, 
Development and Evaluation) system was used to deter-
mine recommendations for each standard based on quality 
of evidence and strength of recommendation (Guyatt et al, 
2008). Recommendations were judged by the Task Force 
based on weighing up the desirable and undesirable effects 
of the management recommendation, including the cost and 
inconvenience of each. Each Task Force member was asked 
to assign a recommendation for each standard, and the final 
recommendation was based on majority consensus where 
agreement was not unanimous (Box 1).
2 |  STANDARDS
2.1 | Standard 1. Patients with a history 
of cancer should be routinely screened for 
pain at every engagement with a healthcare 
professional. [GRADE 1B]
Supporting patients with cancer‐related pain requires sys-
tematic screening for pain symptoms for both patients in re-
mission and those with ongoing disease (Swarm et al, 2013; 
Trowbridge et al, 1997; Williams et al, 2015). Patients are 
often reluctant to disclose pain as they do not perceive health-
care professionals are interested or have the time, and these 
attitudes are often consolidated because healthcare profes-
sionals rarely ask about pain routinely (Gibbins et al, 2014). 
Screening for pain can be achieved by using routine ques-
tions in consultations; for example “Have you experienced 
pain that interferes with daily activities?,” or by use of paper 
or electronic questionnaires in clinics or on hospital wards, 
such as Numerical Rating Scales (NRS) or Visual Analogue 
Scales (VAS).
BOX 1 GRADE recommendations (Guyatt et al., 
2008)
Grade Recommendations
1A. Strong recommendation, high‐quality evidence
1B. Strong recommendation, moderate‐quality evidence
1C. Strong recommendation, low‐quality evidence
2A. Weak recommendation, high‐quality evidence
2B. Weak recommendation, moderate‐quality evidence
2C. Weak recommendation, low‐quality evidence
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2.2 | Standard 2. Patients identified 
with cancer‐related pain should receive a 
pain assessment when seen by a healthcare 
professional, which at a minimum classifies the 
cause of pain based on proposed ICD‐11 
taxonomy and establishes the intensity and 
impact on quality of life of any pain that they 
report. [GRADE 1B]
Cancer‐related pain has multiple aetiologies including the 
cancer itself (cancer pain) and cancer treatments, particularly 
surgery, chemotherapy (including hormonal, biological and 
immune therapies) and radiotherapy (Bennett, 2017). It can 
originate from visceral, bone or nerve tissues and can have 
nociceptive, neuropathic or inflammatory mechanisms (Falk 
and Dickenson, 2014; Knudsen et al, 2009). It also varies in 
its temporal characteristics: it can be acute or chronic and may 
have continuous or episodic features (Caraceni and Portenoy, 
1999). Persistent cancer pain can lead in some individuals 
to the development of chronic widespread pain induced by 
plastic changes in the somatosensory nervous system) Kosek 
et al, 2016).
Pain may also be caused by comorbid conditions unrelated 
to cancer, and this aetiology accounts for around 10%–20% of 
pains in cancer patients (Bennett et al., 2012; Grond et al., 
1996). Therefore, pain in a cancer patient is not synonymous 
with cancer‐related pain; a clinical assessment must distin-
guish between cancer pain, cancer treatment pain and pain 
from comorbid conditions.
Often, patients experience mixed types of pain simul-
taneously, or pain that changes over time. A detailed di-
agnostic assessment that must be repeated at appropriate 
intervals is therefore often required to guide treatment 
strategies.
A bedside assessment can determine the intensity, aeti-
ology, character and underlying mechanisms of pain leading 
to improvements in pain outcomes (Trowbridge et al, 1997). 
The new proposed ICD‐11 classification for cancer‐related 
pain (Table 1) will enable a standardized taxonomy for clini-
cal practice and research and should be used widely (Bennett 
et al., 2019; Treede et al, 2015). The Brief Pain Inventory 
provides a summary of the severity and impact of the pain 
on the patient’s daily activities (Cleeland and Ryan, 1994). 
Additionally, conditions which can amplify pain expression 
such as distress, anxiety and depression (Laird et al, 2016), 
delirium or effects of alcohol and mis‐used drugs, should be 
incorporated in a structured pain assessment (Table 2).
2.3 | Standard 3. A multimodal pain 
management plan should be agreed with the 
patient who explains the causes of their 
pain and its likely prognosis, the need for 
further investigations, the multimodal 
treatment options, and includes the patient’s 
preferences and goals for treatment. [GRADE 
1C]
Cancer patients with pain are keen to understand the cause of 
their pain, what to expect, options for pain control, and how to 
cope with cancer pain including talking with others and find-
ing help (Bender et al, 2008). Longitudinal interview studies 
reveal that pain is very dynamic and complex for patients and 
that pain control is often a trial and error process that requires 
continuous work (Hackett et al, 2016). Cognitive and other 
side effects of analgesia for cancer‐related pain impact on 
quality of life (Sloot et al, 2015). Patients often try to man-
age by reducing interference from both pain and these side 
effects to maintain as much function as possible. This “trad-
ing‐off” between pain and side effects can impact on medica-
tion adherence and should be acknowledged within the pain 
management plan (Flemming, 2010; Manzano et al, 2014).
The goals of cancer‐related pain management should 
therefore be to reduce the pain and its impact on daily living 
though tailored treatment, and to increase each patient’s abil-
ity for self‐management (Bennett, 2017; Gibbins et al, 2014). 
Helping patients to achieve this balance and identifying 
Level 1 Level 2 Level 3 Level 4
Cancer‐related pain Cancer pain Visceral cancer 
pain
Bone cancer pain
Neuropathic cancer 
pain
Postcancer 
treatment pain
Postcancer 
medicine pain
Painful chemotherapy‐
induced 
polyneuropathy
Postradiotherapy 
pain
Painful radiation‐in-
duced neuropathy
Postcancer surgery 
pain
T A B L E  1  Proposed ICD‐11 
classification of cancer‐related pain
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realistic expectations of treatments (for example that pain 
may be controlled to an acceptable degree rather than relieved 
completely) are important for improved patient outcomes.
The care of many patients with cancer may be provided 
by different healthcare professionals simultaneously, for ex-
ample a surgeon, oncologist or primary care physician. It is 
therefore essential that all healthcare professionals who are 
involved in the care of patients with cancer‐related pain be 
appropriately trained to complete this assessment, to initiate 
evidence‐based treatment and to refer to a competent special-
ist when needed (see standard 7). However, most patients can 
be adequately treated at a nonspecialized care level and on 
an outpatient basis. Proper coordination is required between 
the different healthcare professionals to ensure consistent and 
quality care.
2.4 | Standard 4. Patients should receive 
tailored multimodal treatment which 
reduces the pain and its impact on daily 
living and that may include a combination of 
medicines, nonpharmacological treatments, 
oncological interventions, physical 
rehabilitation and psychosocial or spiritual 
support. [GRADE 1A]
Patients must have access to drugs and other interventions 
which are tailored to them. This means that the treatments are 
believed to be effective in their type of cancer‐related pain, 
and that they are consistent with the patient’s preferences and 
goals for treatment.
Analgesic medication that is appropriate for the patient 
and their pain should be available within 24 hr of a pain as-
sessment where indicated; this must include access to a pre-
scriber as well as access to a dispensed prescription (Table 3).
Prescribers should adhere to regional or national pro-
tocols or evidence‐based guidelines for cancer‐related 
pain (Caraceni et al, 2012; Raphael, Hester, et al, 2010; 
Ripamonti et al, 2012; Swarm et al, 2013) as this improves 
outcomes for patients (Du Pen et al, 1999, Cleeland et al, 
2005).
Although analgesic medications are a cornerstone in the 
management of cancer‐related pain, the use of other modali-
ties and procedures can often improve outcomes.
Access to opioid analgesia is critical for pain related to 
advanced and progressing cancer.
For patients with cancer‐related pain who are in the last 
weeks or days of life, a tailored treatment plan is especially 
important and should anticipate analgesic needs (NICE, 
2015). Medications aimed to treat opioid‐related side effects 
such as laxatives, peripheral opioid antagonists and antiemet-
ics should be readily available.
Opioid analgesia may not always be suitable for long‐term 
management of pain related to cancer treatments (chemother-
apy or surgery) in the context of disease that has been cured 
or is in remission (Boland and Ahmedzai, 2017; O’Brien et 
al., 2017).
History Pain location, onset, duration, severity, quality, 
alleviating and aggravating factors. 
Special emphasis on episodic pain
Impact on mood, usual activities, function, quality of 
life and sleep
Previous pain and treatment history
Ongoing response to treatment, adverse effects
Comorbidities impacting pain (e.g., chronic disease, 
surgery, trauma, mood, cognitions, substance use 
disorder, medications)
Personal characteristics (e.g., age, sex, race, religion, 
culture, language)
Expectations of pain management and current 
understanding of the condition, including what 
significance the patient attaches to the pain
Physical examination (focused 
according to the presenting 
condition)
Relevant, physical, neurological and musculoskeletal 
assessment
Review of clinical records Comorbid diseases, previous chronic pain history, 
age‐related frailty
Investigations Laboratory tests
Imaging studies 
Neurophysiological evaluations
T A B L E  2  Structured pain assessment
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Access to oncological and surgical management op-
tions to control pain should be available regionally within 
each country. For example, radiotherapy for bone metas-
tases, spinal stabilization, surgical fixation of patholog-
ical fractures, vertebroplasty or palliative debulking of 
tumour.
2.5 | Standard 5. Support and advice for self‐
management should be provided [GRADE 1A]
Self‐management is the capability of a patient to manage 
their pain, their analgesic treatments and the physical and 
psychological consequences of living with cancer‐related 
pain (Johnston et al, 2014). This involves a number of skills 
and activities including getting the right information, man-
aging practical tasks and emotions, solving problems and 
knowing what to do when symptoms get worse or more 
help is needed (Schumacher et al, 2014). Most patients want 
help to manage themselves, but their ability to do this is in-
fluenced by their emotional state and their physical health.
Addressing concerns about pain and strong opioids, 
and providing strategies that help patients though provi-
sion of educational materials, improve patient outcomes 
and should be routine practice (Bennett et al, 2009; 
Oldenmenger et al, 2018; Sheinfeld Gorin et al., 2012). 
This information must cover how to take analgesia, the 
likely effectiveness of this, how to monitor side effects, 
plans for further follow‐up, and how to get help especially 
out of hours. All members of the healthcare team have a 
role in supporting self‐management including doctors, 
nurses pharmacists and others.
2.6 | Standard 6. The pain management 
plan should be reviewed regularly to assess 
outcomes and plan longer‐term care [GRADE 
1B]
Although patients understandably express that they want to 
be pain free, in general, they do not actually expect their pain 
to go completely (Gibbins et al, 2014). Most patients seem to 
determine whether their pain is controlled by whether or not 
they can perform activities or tasks and maintain relationships 
with family or friends. The outcome in terms of the balance 
of residual pain and functioning is individually determined.
Patients should know who is responsible for reviewing their 
pain management plan, when this review is expected to take 
place and whether this can be done face‐to‐face, by telephone or 
digital technology (Adam et al., 2017). Contact information for 
out of hours support should be easily accessible. Telephone sup-
port from a nurse or pharmacist integrated with electronic symp-
tom monitoring is an effective method of follow‐up for pain and 
analgesia (Kroenke et al, 2010; Oldenmenger et al, 2011).
2.7 | Standard 7. Patients should be 
referred for more specialist advice and 
treatment if pain is not improving within 
a short time or if they are experiencing 
intolerable side effects of analgesia [GRADE 
1C]
Patients should be referred for specialist support if pain is 
not well controlled despite initial management or the pain 
has been identified as complex. Specialist support must be 
Drug class Examples
Simple analgesia Paracetamol 
Nonsteroidal anti‐inflammatory drugs (NSAIDs) including coxibs
Opioids Opioids for moderate intensity pain: 
Codeine, dihydrocodeine, tramadol 
Opioids for moderate to severe intensity pain: 
Immediate release opioids as oral and injectable formulations (mor-
phine, oxycodone, hydromorphone); Sustained release opioids as oral 
(morphine, oxycodone, tapentadol, hydromorphone;) and transdermal 
(fentanyl, buprenorphine) formulations, 
Opioids for specialist use only 
Rapid onset transmucosal fentanyl based formulations 
Methadone
Antidepressants Amitriptyline, imipramine, duloxetine, venlafaxine
Antiepileptics Gabapentin, pregabalin, carbamazepine
Corticosteroids Prednisolone, dexamethasone
Bisphosphonates Pamidronate, Zoledronate
Monoclonal 
antibodies
Denosumab, Tanezumab
Other Topical lidocaine; ketamine (specialist use only)
T A B L E  3  Essential analgesic drugs
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available regionally within each country in the form of spe-
cialist multidisciplinary pain services, oncology services 
including radiotherapy and palliative care services. Access 
to specialist services for pain that is insufficiently respond-
ing to standard care should be readily available regionally 
within one week (IASP, 2018). This includes access to 
advanced pain management techniques such as intrathecal 
pumps and neuro‐ablative techniques (Bruel and Burton, 
2016; Smith et al, 2002; Vayne‐Bossert et al, 2016). Early 
referral to specialist services is needed when pain is com-
plex or not responding to initial treatment, rather than wait-
ing until all conventional approaches have been exhausted 
and the patient is too unwell for advanced pain manage-
ment intervention.
Patients who present with severe uncontrolled pain, sig-
nificant drug related adverse events or extreme psychologi-
cal distress should also be referred urgently to a specialized 
care facility (IASP, 2018). Healthcare professionals should 
be aware of appropriate specialized care facilities with spe-
cific and targeted multidimensional expertise in the manage-
ment of cancer pain nationally. Established referral pathways 
should exist between oncology, pain and palliative care ser-
vices to coordinate care while taking into account patient and 
family expectations.
With improved early cancer diagnosis and enhanced 
treatments, many patients are now living with cancer as a 
chronic disease. Increasing numbers of patients experience 
cure or prolonged remission and are regarded as cancer sur-
vivors. Some of these patients will continue to experience 
pain which negatively affects their quality of life (Glare et 
al, 2014). Some patients may continue to use high doses 
of opioid, previously required for adequate pain control, 
but which are no longer needed while causing side effects. 
These patients require more specialist help which is likely 
to include long‐term self‐management plans, medication 
weaning plans and pain rehabilitation and occupational 
therapy interventions (Paice et al, 2016). Such plans are 
typically offered by chronic pain management programs 
and pain clinicians with a special interest in opioid man-
agement. Each country should have national guidance on 
managing and referring patients with long‐term pain from 
cancer treatments.
2.8 | Standard 8. Healthcare professionals 
who treat patients with cancer should receive 
ongoing education and training in order to 
undertake basic pain assessment, initiate 
basic management, and learn about correctly 
referring for more specialist support [GRADE 
1C]
Significant gaps in knowledge on cancer pain diagno-
sis and management by healthcare professionals are well 
documented in the medical literature, leading to inadequate 
relief in a substantial number of patients with cancer pain 
(Oldenmenger et al, 2009). Proper education and training 
is therefore essential. EFIC recommends its chapters to de-
velop educational programs on cancer pain at undergradu-
ate level (medical and nursing schools), postgraduate level 
for all healthcare professions who are involved in the care of 
patients with cancer, and finally within specialized programs 
within training in pain and palliative medicine. An example 
of the contents of such educational programs can be found 
in EFIC’s Core Curriculum for Pain Management (European 
Pain Federation, 2017).
2.9 | Standard 9. Regular review of service 
outcomes for all patients with cancer pain 
should be in place [GRADE 1C]
Regular review of outcomes for patients enables services to 
identify areas for improvement, focusing on safety and effi-
cacy data of various methods of pain control. Novel methods 
for supporting patients to complete outcome measures are 
needed, for example using electronic or digital technology 
(Adam et al., 2017).
2.10 | Standard 10. Each EFIC chapter 
should have national evidence or consensus‐
based guidelines in place for cancer‐related 
pain [GRADE 1C]
Many international and national guidelines on cancer pain 
assessment and treatment are available but they may not be 
suitable for all countries (Piano et al, 2014). EFIC recom-
mends that its chapters should produce an appropriate treat-
ment guideline for cancer‐related pain that is valid for the 
circumstances according to each country's needs acknowl-
edging variations in access to drugs and other treatments, 
and respecting social and cultural identity. Such guidelines 
can be adapted from existing international or national guide-
lines in other countries. Production of lay versions which 
can be understood by nonhealthcare professionals should be 
considered.
We recommend that each country will develop a mecha-
nism, by either professional organizations or through regu-
latory authorities, to monitor and assess the implementation 
and usage of national guidelines and European standards.
3 |  SUMMARY
The 10 standards presented are aimed to improve cancer pain 
management and reduce variation across Europe. We believe 
that adoption of these standards by all 37 countries will pro-
mote the quality of care of patients with cancer‐related pain 
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and reduce unnecessary suffering. EFIC will continuously sup-
port enhancing the quality of cancer pain management through 
its pain schools, special sessions in conferences and reviewing 
and when necessary revising this document in the future.
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